Teva Pharmaceutical Industries Ltd (TEVA) Expected to Announce Quarterly Sales of $4.77 Billion

Equities analysts expect that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will post sales of $4.77 billion for the current quarter, according to Zacks. Six analysts have issued estimates for Teva Pharmaceutical Industries’ earnings, with the highest sales estimate coming in at $4.96 billion and the lowest estimate coming in at $4.61 billion. Teva Pharmaceutical Industries posted sales of $5.63 billion in the same quarter last year, which suggests a negative year-over-year growth rate of 15.3%. The firm is scheduled to announce its next quarterly earnings report on Thursday, May 10th.

On average, analysts expect that Teva Pharmaceutical Industries will report full year sales of $4.77 billion for the current year, with estimates ranging from $18.49 billion to $18.80 billion. For the next year, analysts anticipate that the business will post sales of $18.04 billion per share, with estimates ranging from $17.67 billion to $18.65 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Teva Pharmaceutical Industries.

How to Become a New Pot Stock Millionaire

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 16.43% and a negative net margin of 72.66%. The firm had revenue of $5.46 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same period last year, the business posted $1.38 earnings per share. The firm’s revenue for the quarter was down 15.9% on a year-over-year basis.

A number of brokerages have recently commented on TEVA. Jefferies Group began coverage on Teva Pharmaceutical Industries in a report on Tuesday, March 20th. They set a “hold” rating and a $19.00 price target on the stock. Zacks Investment Research lowered Teva Pharmaceutical Industries from a “hold” rating to a “sell” rating in a report on Friday, January 12th. UBS set a $20.00 target price on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Monday, December 18th. Credit Suisse Group raised Teva Pharmaceutical Industries from an “underperform” rating to a “neutral” rating and lifted their target price for the stock from $8.00 to $20.00 in a report on Friday, December 15th. Finally, Royal Bank of Canada raised Teva Pharmaceutical Industries from an “underperform” rating to a “sector perform” rating and set a $18.00 target price on the stock in a report on Friday, February 9th. Eleven research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries currently has a consensus rating of “Hold” and an average price target of $19.67.

NYSE TEVA traded up $0.42 during trading hours on Friday, hitting $17.30. The company had a trading volume of 5,830,706 shares, compared to its average volume of 15,523,542. Teva Pharmaceutical Industries has a fifty-two week low of $10.85 and a fifty-two week high of $33.82. The company has a debt-to-equity ratio of 1.91, a current ratio of 0.86 and a quick ratio of 0.58. The firm has a market capitalization of $17,164.88, a PE ratio of 4.39, a P/E/G ratio of 1.47 and a beta of 0.67.

In other news, EVP Mark Sabag sold 5,050 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $19.68, for a total transaction of $99,384.00. Following the sale, the executive vice president now owns 44,517 shares of the company’s stock, valued at approximately $876,094.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 10,734 shares of company stock worth $204,795 in the last three months. 7.10% of the stock is owned by insiders.

A number of hedge funds have recently made changes to their positions in the stock. Calton & Associates Inc. acquired a new position in Teva Pharmaceutical Industries in the fourth quarter worth $108,000. Fieldpoint Private Securities LLC bought a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth $171,000. Global Financial Private Capital LLC bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth $193,000. Wetherby Asset Management Inc. bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth $197,000. Finally, Sigma Planning Corp bought a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at about $214,000. 58.20% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Teva Pharmaceutical Industries Ltd (TEVA) Expected to Announce Quarterly Sales of $4.77 Billion” was first published by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/3343789/teva-pharmaceutical-industries-ltd-teva-expected-to-announce-quarterly-sales-of-4-77-billion.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Analysts Set Granite Construction  PT at $73.00
Analysts Set Granite Construction PT at $73.00
Salesforce.com  Receives Consensus Recommendation of “Buy” from Analysts
Salesforce.com Receives Consensus Recommendation of “Buy” from Analysts
Reliance Steel & Aluminum  and L.B. Foster  Critical Survey
Reliance Steel & Aluminum and L.B. Foster Critical Survey
Head to Head Survey: ZTE  and Absolute Software
Head to Head Survey: ZTE and Absolute Software
Dovu  Price Up 54.1% This Week
Dovu Price Up 54.1% This Week
Critical Survey: Dorian LPG  & Global Ship Lease
Critical Survey: Dorian LPG & Global Ship Lease


Leave a Reply

© 2006-2018 Ticker Report. Google+.